ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Outcome measures"

  • Abstract Number: 2113 • ACR Convergence 2022

    Improvement in Key PsA Core Domains with Guselkumab Treatment in an Enriched Population of ACR20 Non-Responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies

    Dennis McGonagle1, Derek Haaland2, Philip Helliwell3, A. Marilise Marrache4, May Shawi5, Emmanouil Rampakakis6, Peter Nash7, Fedra Irazoque Palazuelos8 and Arthur Kavanaugh9, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 2The Waterside Clinic, Oro Medonte, ON, Canada, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 4Janssen Inc., Dollard-des-Ormeaux, QC, Canada, 5Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 6McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, 7School of Medicine, Griffith University, Sunshine Coast, Australia, 8Angeles Mocel Hospital; Universidad Autónoma de México, Ciudad de México, Mexico, 9University of California San Diego, La Jolla, CA

    Background/Purpose: Despite available PsA treatments, a portion of PsA patients (pts) does not achieve improvements in PsA signs and symptoms according to ACR response criteria.…
  • Abstract Number: 0168 • ACR Convergence 2022

    Semiquantitative Thigh Magnetic Resonance Imaging (tMRI) in Determining Skeletal Muscle Outcomes at Baseline and on Follow up in Idiopathic Inflammatory Myopathies (IIMs)

    Mamatha Gorijavolu1, Devender Bairwa2, Chengappa Kavadichanda3, Sai Kumar Dunga4, Aishwarya Gopal5, Vir Singh Negi6 and Molly Thabah1, 1Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India, 2Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, Puducherry, India, 3JIPMER, Pondicherry, Puducherry, India, 4Jawaharlal institute of postgraduate medical education and research, Srikakulam, India, 5Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, Puducherry, India, 6AIIMS Bilaspur, Puducherry, Puducherry, India

    Background/Purpose: Semiquantitative scoring of thigh Magnetic Resonance Imaging (tMRI) has shown contradictory results in associating muscle inflammation, damage, and clinically assessed muscle weakness. Moreover, there…
  • Abstract Number: 0392 • ACR Convergence 2022

    Performance of Clinical, Laboratory and Imaging Features for the Diagnosis of Axial Spondyloarthritis – A Systematic Literature Review

    Ana Bento da Silva1, Helena Lourenço2, Sofia Ramiro3, Louise Falzon4, Jaime Branco5, Désirée van der Heijde6, Robert Landewé7 and Alexandre Sepriano8, 1Rheumatology department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal, 2Serviço de Reumatologia, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal, 3Leiden University Medical Center, Leiden, Netherlands, 4Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom, 5Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal, 6Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, 7Amsterdam University Medical Center, Meerssen, Netherlands, 8Leiden University Medical Centre, Portela Loures, Portugal

    Background/Purpose: The Berlin algorithm for the diagnosis of axial spondyloarthritis (axSpA) was developed more than 15 years ago (2004). Since then, new studies suggest that…
  • Abstract Number: 0858 • ACR Convergence 2022

    Predicting the Occurrence of Drug-Free Inactive Disease Two Years After Diagnosis of Non-Systemic Juvenile Idiopathic Arthritis

    Melissa Mannion1, Chen Chen2, Olha Halyabar3, Susan Paetkau4, Tingting Qiu5 and Bin Huang6, 1University of Alabama at Birmingham, Birmingham, AL, 2Cincinnati Children's Hospital Medical Center, Taipei, Taiwan, 3Children's Hospital/Boston Medical Center, Boston, MA, 4The Hospital for Sick Children, Toronto, ON, Canada, 5Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 6Cincinnati Children's Hospital Medical Center, Cinciannati, OH

    Background/Purpose: The goal of treatment for juvenile idiopathic arthritis (JIA) is inactive disease (ID), but the optimal treatment for each patient to maximize ID and…
  • Abstract Number: 1260 • ACR Convergence 2022

    Tenderness and Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis

    Irina Gessl1, Mihaela Popescu2, Gabriela supp3, Thomas Deimel1, Paul Studenic1, Martina Durechova3, michael zauner3, Josef Smolen1 and Peter Mandl1, 1Medical University of Vienna, Vienna, Austria, 2Department of Rheumatology, Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada, 3Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

    Background/Purpose: In inflammatory arthritis swelling is regarded as a sign of synovitis and is associated with radiographic progression. However, the association of tenderness with radiographic…
  • Abstract Number: 1496 • ACR Convergence 2022

    Do Patients in MDA Report Low Disease Activity Regardless of Which of the MDA Criteria Are Met?

    Sarah Yazji1, Philip Helliwell2, Andra Balanescu3, JUAN CANETE4, Emmanuelle Dernis5, Uta Kiltz6, Ying Ying Leung7, Ennio Lubrano8, Ana-Maria Orbai9, PENELOPE PALOMINOS10, Rossana Scrivo11, Josef Smolen12, Sandra Meisalu13, Maarten de Wit14, Laure Gossec15 and Laura Coates16, 1University of Oxford, Oxford, United Kingdom, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 3University of Medicine and Pharmacy Carol Davila, Bucharest, Romania, 4Rheumatology Department, Hospital Clinic and IDIBAPS, Barcelona, Spain, 5LE MANS general hospital, LE MANS, France, 6Rheumazentrum Ruhrgebiet, Herne, Germany, 7Rheumatology Department, Singapore General Hospital, Singapore, Singapore, 8Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute ‘‘Vincenzo Tiberio’’, Università degli Studi del Molise, Campobasso, Italy, 9Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 10Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil, 11Rheumatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy, Roma, Rome, Italy, 12Medical University of Vienna, Vienna, Austria, 13East Tallinn Central Hospital, Tallinn, Estonia, 14Patient research partner, Amsterdam, Netherlands, 15Sorbonne Université, Paris, France, 16Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom

    Background/Purpose: The Minimal Disease Activity (MDA) criteria evaluate PsA disease activity and response to treatment and are defined as meeting ≥5 criteria: tender joint count…
  • Abstract Number: 1952 • ACR Convergence 2022

    Burden of Disease in Refractory Rheumatoid Arthritis

    Kristin Wipfler1, Bobby Kwanghoon Han2, Urbano Sbarigia3, Federico Zazzetti4, Anna Sheahan5, Iris Lin6, Patricia Katz7, Evo Alemao8 and Kaleb Michaud9, 1FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 2Division of Rheumatology, University of Washington, Seattle, WA, 3Johnson & Johnson, Beerse, Belgium, 4Janssen Medical Affairs Global Services, LLC, Buenos Aires, Argentina, 5Janssen Research and Development, Chapel Hill, NC, 6Janssen, Horsham, PA, 7UCSF, San Rafael, CA, 8Janssen, Princeton, NJ, 9University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Despite major advances in RA treatment and the improved outcomes that have been associated with the expanding number of advanced therapies available, a substantial…
  • Abstract Number: 2138 • ACR Convergence 2022

    Real-world Persistence and Treatment Patterns in Psoriatic Arthritis Patients Treated with Anti-IL17 Therapy

    BEATRIZ E. JOVEN1, Concepción Fito Manteca2, Enrique Rubio3, Enrique Raya Álvarez4, Alba Pérez5, Raquel Hernández6, Sara Manrique Arija7, Mercedes Núñez8, Silvia Díaz8, Luis Trancho8, Sebastian Moyano8, Alessandra Lacetera9, Noelia Alfaro-Oliver9 and Rosario Garcia-Vicuña10, 1Hospital Universitario 12 de Octubre, Madrid, Spain, 2Hospitalario de Navarra, Pamplona, Spain, 3Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, 4Hospital Universitario San Cecilio, Granada, Spain, 5Hospital Puerta del Mar, Cádiz, Spain, 6Virgen de Valme University Hospital, Sevilla, Spain, 7Hospital Regional Universitario Málaga, Málaga, Spain, 8Lilly, Alcobendas, Spain, 9OXON Epidemiology, Madrid, Spain, 10Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain

    Background/Purpose: Interleukin-17A inhibitors (anti-IL17) have provided an additional treatment option in the management of the psoriatic arthritis (PsA). This study aims to describe the patient…
  • Abstract Number: 0172 • ACR Convergence 2022

    Clinical Characteristics and Outcomes of Inflammatory Myositis Related Interstitial Lung Disease: A 15 Year Retrospective Study

    Ian Ward1, Elizabeth Pepper2 and Geoffrey Loh2, 1United States Army, Evans, GA, 2DDEAMC, Ft. Gordon, GA

    Background/Purpose: Interstitial lung disease (ILD) is a common complication of Idiopathic Inflammatory Myopathy (IIM). This extra-muscular manifestation is a significant source of morbidity and has…
  • Abstract Number: 0418 • ACR Convergence 2022

    Real World Evidence on Disease Activity in Patients with Ankylosing Spondylitis Treated with Tumour Necrosis Factor Inhibitors and/or Nonsteroidal Anti-Inflammatory Drugs in Routine Care

    Jan Brandt-Juergens1, Judith Haschka2, Richard Finsterwalder3, Aurélie Casier4, Angela Kill5 and Stéphanie Dierckx6, 1Rheumatologische Schwerpunktpraxis, Berlin, Germany, 2Karl Landsteiner Institute for Gastroenterology and Rheumatology Rheuma-Zentrum Wien-Oberlaa, Vienna, Austria, 3Novartis Pharma GmbH, Vienna, Austria, 4N.V. Novartis Pharma S.A., Vilvoorde, Belgium, 5Novartis Pharma GmbH, Nuremberg, Germany, 6CHU UCL Namur- Site Godinne, Yvoir, Belgium

    Background/Purpose: Ankylosing Spondylitis (AS) is an inflammatory rheumatic disease affecting the axial skeleton (1), with a prevalence of up to 0.5% in Europe (2; 3),…
  • Abstract Number: 0890 • ACR Convergence 2022

    Long Term Efficacy of a 2-year MRI Treat-to-target Treatment Strategy on Disease Activity, MRI Inflammation and Physical Function in Rheumatoid Arthritis Patients in Clinical Remission: Five Year Follow-up of the IMAGINE-RA Cohort

    Signe Møller-Bisgaard1, Kim Hørslev-Petersen2, Daniel Glinatsi3, Bo Ejbjerg4, Merete Lund Hetland5, Jakob Møllenbach Møller6, Robin Christensen7, Sabrina Mai Nielsen8, Mikael Boesen9, Kristian Stengaard-Pedersen10, Ole Rintek Madsen11, Bente Jensen12, Jan Alexander Villadsen13, Ellen Margrethe Hauge10, Oliver Hendricks2, Hanne Merete Lindegaard14, Niels Steen Krogh15, Anne Grethe Jurik16, Henrik Thomsen17 and Mikkel Østergaard18, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, 2Department of Rheumatology, Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, 3Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, 4Department of Rheumatology, Slagelse Hospital, Slagelse, Denmark, 5Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark, 6Department of Radiology, Herlev-Gentofte Hospital, Copenhagen, Denmark, 7Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, 8The Parker Institute, Section for Biostatistics and Evidence-Based Research, Bispebjerg-Frederiksberg Hospital, Frederiksberg, Denmark, 9Department of Radiology, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark, 10Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 11Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Herlev-Gentofte, Copenhagen, Denmark, 12Center for Rheumatology and Spine Diseases, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark, 13Department of Rheumatology, Silkeborg Hospital, Silkeborg, Denmark, 14Department of Rheumatology, Odense University Hospital, Odense, Denmark, 15ZiteLab ApS, Frederiksberg, Denmark, 16Department of Radiology, Aarhus University Hospital, Aarhus, Denmark, 17Department of Radiology, Herlev and Gentofte Hospital, Copenhagen, Denmark, 18Rigshospitalet, University of Copenhagen, Glostrup, Denmark

    Background/Purpose: Targeting MRI remission in rheumatoid arthritis (RA) patients in clinical remission may improve long term clinical, functional and MRI outcomes. The purpose of the…
  • Abstract Number: 1261 • ACR Convergence 2022

    Scoring Structural Damage in Rheumatoid Arthritis by Ultrasound: Results from a Delphi Process and Web-Based Reliability Exercise by the OMERACT Ultrasound Working Group

    Peter Mandl1, Irina Gessl1, Georgios Filippou2, Silvia Sirotti3, Lene Terslev4, Carlos Pineda5, Helen Keen6, Marina Backhaus7, David Bong8, Edoardo Cipolletta9, Paz Collado10, Christian Dejaco11, Andrea Delle Sedie12, Christina Duftner13, Hilde Berner Hammer14, Annmaria Iagnocco15, Zunaid Karim16, Esperanza Naredo17, Wolfgang Schmidt18, Marcin Szkudlarek19, Giorgio Tamborrini20, Priscilla Wong21, Emilio Filippucci9, Peter Balint22 and Maria-Antonietta D'Agostino23, 1Medical University of Vienna, Vienna, Austria, 2Rheumatology Department, Luigi Sacco University Hospital, Siena, Italy, 3Università degli Studi di Milano, Milano, Italy, 4Copenhagen University Hospital Glostrup, Glostrup, Denmark, 5Instituto Nacional de Rehabilitacion, Ciudad de México, Mexico, 6University of Western Australia, Perth, Australia, 7Park-Klinik Weissensee Academic Hospital of the Charité, Berlin, Germany, 8Instituto Poal de Reumatologia, Universitat de Barcelona, Barcelona, Spain, 9Polytechnic University of Marche, Rheumatology Unit, Department of Clinical and Molecular Sciences, "Carlo Urbani" Hospital, Jesi, Italy, 10Division of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain, 11Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, and Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, 12University of Pisa, Pisa, Pisa, Italy, 13Department of Internal Medicine, Medical University of Innsbruck, Innsbruck, Austria, 14Diakonhjemmet hospital, Jar, Norway, 15Academic Rheumatology Centre, University of Turin, Turin, Italy, 16Department of Rheumatology, Mid Yorkshire NHS Trust, Yorkshire, United Kingdom, 17Hospital General Universitario Gregorio Marañón and Complutense University, Madrid, Spain, 18Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology, Berlin-Buch, Berlin, Germany, 19Department of Rheumatology, Copenhagen University Hospital at Køge, Copenhagen, Denmark, 20Ultrasound Center and Institute for Rheumatology, Basel, Switzerland, 21Division of Rheumatology, The Chinese University of Hong Kong, Hong-Kong, Hong Kong, 223rd. Department of Rheumatology, National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, 23Catholic University of Sacred Heart, Roma, Italy

    Background/Purpose: Structural damage in rheumatoid arthritis (RA) includes bone erosions, cartilage changes, and joint malalignment; historically evaluated with conventional radiography. Ultrasound (US) has been shown…
  • Abstract Number: 1499 • ACR Convergence 2022

    The Impact of Cycling Among Tumor Necrosis Factor Inhibitors on Disease Control in Patients with Axial Spondyloarthritis: A Study from the CorEvitas PsA/SpA Registry

    Philip J Mease1, Robert McLean2, Taylor Blachley2, Nicole Middaugh2, Manish Mittal3, Jerry Clewell3, Heather Jones4 and Alexis Ogdie5, 1Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 2CorEvitas, LLC, Waltham, MA, 3AbbVie, Inc., North Chicago, IL, 4AbbVie, Inc., Chicago, IL, 5Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Axial spondyloarthritis (AxSpA) is a chronic inflammatory disease characterized by inflammatory back pain, morning stiffness, and reduced functional capacity. Approved therapies for AxSpA include…
  • Abstract Number: 1960 • ACR Convergence 2022

    Impact of Delaying Initiation of Methotrexate by One Month on the Outcome of RA at One Year

    Theresa Than1, Emmanuelle Dernis2, Olivier BROCQ3, Bruno Fautrel4, Helena HUGUET5, Liana Euller-Ziegler6, Lindsay BUSTAMENTE-CENCI6, Olivier Vittecoq7, Marie-christine PICOT5, Cédric Lukas8, Claire DAIEN9, Charlotte Hua10, Marlène Genty5, Helene Che5, Anouck REMY-MOULARD11, Frederic LIOTE12, Martin Soubrier13, Cécile GAUJOUX-VIALA14, Arnaud Constantin15, Alain Saraux16, Emilie Ducourau17, Stephanie RIST18, CARINE SALLIOT19, Nada IBRAHIM-NASSER18, Clara qUINTEN18, Vincent Goeb20 and Jacques Morel1, 1University and CHU Montpellier, Montpellier, France, 2LE MANS general hospital, LE MANS, France, 3Centre hospitalier Princesse-Grace, Monaco, France, 4Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France, 5CHU Montpellier, Montpellier, France, 6CHRU Nice, Nice, France, 7CHU de Rouen, ROUEN, France, 8University Hospital Centre Montpellier, University of Montpellier, Montpellier, France, 9University Hospital, Saint-Gély-du-Fesc, France, 10La Lettre du Rhumatologue, Paris, France, 11CHU Montpellier, Montpellier, Chad, 12University of Paris, Paris, France, 13Gabriel-Montpied Hospital, Clermont-Ferrand, France, 14CHU Nîmes, Univ Montpellier (IDESP), Nîmes, France, 15Toulouse University Hospital, Toulouse, France, 16CHU Brest, Brest, France, 17CH Orleans, Chambray Les Tours, France, 18CH orleans, Orleans, France, 19CHR orleans, Orleans, France, 20CHU Amiens, Amiens, France

    Background/Purpose: It is recommended that vaccinations should be performed prior to start methotrexate (MTX) knowing that delaying initiation of background therapy may have an impact…
  • Abstract Number: 2139 • ACR Convergence 2022

    Sustained Response to Guselkumab Regardless of Baseline Demographic, Disease, and Medication Characteristics in Patients with Active Psoriatic Arthritis and an Inadequate Response to TNF Inhibitors: Results from a Phase 3b Trial

    Iain B McInnes1, Philipp Sewerin2, Mohamed Sharaf3, Michela Efficace4, May Shawi5, Michelle Perate6, Miriam Zimmermann7 and Laura Coates8, 1Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, 2Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, 3Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, 4Janssen Cilag SpA, Imperia, Italy, 5Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 6Janssen Scientific Affairs, LLC, Horsham, PA, 7Janssen Scientific Affairs, LLC, Zug, Switzerland, 8Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom

    Background/Purpose: Guselkumab (GUS) is a human monoclonal antibody targeting the IL-23 p19 subunit. In the Phase 3b COSMOS trial (NCT03796858), GUS significantly improved disease signs/symptoms…
  • « Previous Page
  • 1
  • …
  • 23
  • 24
  • 25
  • 26
  • 27
  • …
  • 49
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology